Medical Professionals Reference (MPR)Gene Therapy Casgevy Approved for Younger SCD and TDT Patients

📋 Regulatory Action / Label Change

Casgevy (exagamglogene autotemcel) was previously approved for patients aged 12 years and older with sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The FDA has now expanded eligibility to children as young as 2 years following positive pediatric phase 3 results.

Clinical Considerations

• All 8 efficacy-evaluable pediatric SCD patients achieved 12 months free from severe vaso-occlusive crises.
• In pediatric TDT, 8 of 9 efficacy-evaluable patients achieved 12-month transfusion independence.
• Approval for children aged 2 to less than 5 years relied on extrapolated clinical and product-characteristic data.
• Grade 3-4 adverse events included mucositis, febrile neutropenia, cytopenias, and decreased appetite.

Practice Applications

• Recognize expanded eligibility for pediatric patients with SCD and TDT.
• Review gene therapy candidacy earlier in the disease course.
• Monitor treatment-related hematologic toxicities and conditioning risks.
• Interpret pediatric outcomes within the context of limited sample sizes.